Core Insights - PathoCare Holdings has received a private third-party tender offer for the secondary purchase of shares, indicating an implied company valuation of approximately $1.75 billion [1] - The company previously underwent a $150 million venture investment, recapitalization, and a secondary tender offer at a $500 million valuation [1][5] - An independent financial advisory firm has been appointed to conduct a formal fairness opinion and updated valuation review following the latest tender offer [2] Financial Activities - The earlier $500 million valuation was assigned by Lehrer Financial, a financial consulting firm [2] - PathoCare Holdings has increased the size of its planned private equity financing round from up to $25 million to up to $50 million due to heightened institutional interest and market demand [3] Use of Proceeds - The company plans to utilize the proceeds from the proposed financing to accelerate product development, expand intellectual property, enhance regulatory readiness, and commercialize its flagship diagnostic platform, including the PathoWand point-of-care system [4] Management Commentary - PathoCare Holdings' chairman, Mychal Jefferson, stated that the significant third-party tender offer reflects growing institutional confidence in the long-term potential of the diagnostic platform [4] - The Board is committed to proceeding with discipline and transparency by commissioning an independent fairness opinion before making final decisions [5]

Industry Overview - Asia is projected to become the world's fastest-growing healthcare market, reaching US$5 trillion by 2030, driven by aging populations and a growing middle class [1] - The increasing demand for healthcare products and services is expected to benefit healthcare providers, health-tech innovators, and health-related infrastructure across the region [1][13] Raffles Medical Group (SGX: BSL) - Raffles Medical Group reported a revenue growth of 3.5% year-on-year to S$378.4 million for the first half of 2025 [2] - The Raffles Health Insurance segment saw a revenue increase of 10% year-on-year to S$94.9 million, while Hospital Services experienced a gain of 3.8% year-on-year to S$174 million [2] - Profits rose by 5% year-on-year to S$32.5 million, primarily driven by Hospital Services segment profits increasing by 24.3% year-on-year to S$17.7 million [3] - The company is expanding its presence in China through strategic partnerships with Shanghai Renji Hospital and Chongqing's First Affiliated Hospital [4] - RMG has a trailing price-to-earnings (PE) ratio of over 29, indicating investor optimism regarding its future growth [4][5] Abbott Laboratories (NYSE: ABTT) - Abbott Laboratories reported a 6.9% year-on-year revenue gain to US$11.4 billion for the third quarter of 2025 [6] - The diabetes care medical devices segment contributed significantly, with sales growth of 19.3% year-on-year to US$2 billion, driven by the success of the FreeStyle Libre continuous glucose monitors [7] - Abbott launched new products in India, including the FreeStyle Libre 2 Plus and AVEIR™ DR, to capture the growing demand for medical devices in Asia [8] - The company maintains a healthy dividend yield of 1.9% and a PE ratio of 16, reflecting solid fundamentals [9] ParkwayLife REIT (SGX: C2PU) - ParkwayLife REIT experienced an 8.2% year-on-year increase in gross revenue to S$117.3 million for the first nine months of 2025 [10] - Net property income rose by 8.1% year-on-year to S$110.7 million, while distribution per unit (DPU) increased by 2.3% year-on-year to S$0.1156 [10] - Growth is attributed to step-up lease agreements and acquisitions, including nursing homes in France and Japan [11] - The REIT has a healthy gearing of 35.8%, well below the regulatory limit, indicating a strong balance sheet [12] Investment Opportunities - The Asia healthcare boom represents a long-term market shift rather than a cyclical upswing, driven by increased purchasing power and an aging population [13] - The three highlighted companies tap into different aspects of the healthcare value chain, presenting early investment opportunities in resilient stocks with structural upside [14]

Core Viewpoint - High valuations do not necessarily prevent further market-beating gains but tend to increase volatility, with Edwards Lifesciences (EW) exemplifying this trend [1]. Group 1 - Edwards Lifesciences continues to demonstrate impressive growth relative to its size [1].

Core Viewpoint - A class action securities lawsuit has been filed against Integer Holdings Corporation, alleging securities fraud that affected investors between July 25, 2024, and October 22, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Integer Holdings Corporation materially overstated its competitive position in the electrophysiology manufacturing market [2]. - It is alleged that despite claims of strong visibility into customer demand, the company was experiencing a sustained deterioration in sales related to two of its electrophysiology devices [2]. - The complaint further asserts that Integer mischaracterized its electrophysiology devices as a long-term growth driver for its cardio & vascular segment, leading to materially false and misleading statements about the company's business and prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the relevant time frame have until February 9, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4].

NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Inspire Medical Systems, Inc. ("Inspire Medical Systems, Inc." or the "Company") (NYSE: INSP) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Inspire Medical Systems, Inc. investors who were adversely affected by alleged securities fraud between August 6, 2024 and August 4, 2025. Follow the link below to get more information and be contacted by a member of our team ...

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][3]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its "operational readiness" for the Inspire V launch, which concealed significant operational failures that ultimately led to a drastic cut in guidance and a stock price crash [3][5]. - Key undisclosed operational issues include: - Medicare claims software updates were not effective until July 1, 2025, delaying the rollout and revenue generation [4]. - An excess inventory of the older Inspire IV device impacted demand for the new Inspire V, leading to a significant reduction in 2025 earnings per share (EPS) guidance by over 80% [4]. - Many treatment centers had not completed necessary training and onboarding for the new device, contributing to a $42.04 per share drop and a 32.4% decline in stock value [4]. Group 2: Legal Actions and Investor Guidance - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman before the Lead Plaintiff Deadline of January 5, 2026, to discuss their legal rights [2][3]. - Hagens Berman is focusing on the alleged concealment of critical operational issues, emphasizing that the stock collapse was due to management prioritizing a narrative over operational reality [5].

Core Viewpoint - Nyxoah will present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its innovative treatment for Obstructive Sleep Apnea (OSA) through the Genio system [1][2]. Company Overview - Nyxoah is a medical technology company focused on developing and commercializing solutions for OSA, with its lead product being the Genio system, which is a leadless and battery-free hypoglossal neurostimulation therapy [3]. - The company aims to improve the quality of life for OSA patients, who are at increased risk for mortality and cardiovascular issues [3]. Product Development and Regulatory Approvals - The Genio system received its European CE Mark in 2019 following the successful completion of the BLAST OSA study [4]. - Nyxoah has completed two IPOs, one on Euronext Brussels in September 2020 and another on NASDAQ in July 2021 [4]. - The company expanded its therapeutic indications to include Complete Concentric Collapse (CCC) patients after positive outcomes from the BETTER SLEEP study, which are currently contraindicated in competitors' therapies [4]. - Nyxoah also announced positive results from the DREAM IDE pivotal study and received FDA approval in August 2025 for a subset of adult patients with moderate to severe OSA [4].

As filed with the U.S. Securities and Exchange Commission on December 29, 2025. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) Delaware 6770 85-1728920 (Primary Standard Industrial Classification Code No.) Registration No. 333-291237 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QT Imaging Holdings, Inc. (I.R.S. Employer Identifi ...

As filed with the U.S. Securities and Exchange Commission on December 29, 2025. Registration No. 333-291237 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QT Imaging Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) Delaware 6770 85-1728920 (Primary Standard Industrial Classification Code No.) (I.R.S. Employer Identifi ...

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to a range of $1.840 billion to $1.854 billion from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations. The company also projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6].